KRAS and neoplasm: In fact, tumor-derived exosomes in patients’ bloodstream were shown to contain fractions of tumor genome, transcriptome, and proteome such as KRAS, TP53 mutations in pancreatic and colon cancer (12); mutant/variant EGFRvIII mRNAs in glioblastoma (13); microRNAs in ovarian cancer (14); MET in melanoma (15); and HER2 in breast cancer (16).